

Revision date 19-Dec-2022 Version 2 Page 1/13

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Metoclopramide Injection (Hospira, Inc.)

Product Code(s) PZ03279

Synonyms Metoclopramidum
Trade Name: Not applicable
Chemical Family: Mixture

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used for nausea and vomiting (antiemetic)

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company

Hospira UK Limited

275 North Field Drive Horizon
Lake Forest, Illinois 60045 Honey Lane
1-800-879-3477 Hurley

Maidenhead, SL6 6RJ United Kingdom

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Not classified as hazardous according to Regulation (EC) 1272/2008 and/or other applicable regulations.

2.2. Label elements

Signal word Not Classified

Hazard statements Not classified in accordance with international standards for workplace safety.

2.3. Other hazards

Other hazards An Occupational Exposure Value has been established for one or more of the ingredients

(see Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazard	lous
--------	------

i iazai dous							
Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Metoclopramide (CAS #: 364-62-5)	0.5		206-662-9	Acute Tox 4 (H302)	Not Listed	No data available	No data available
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5	Skin Corr.1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available
+ Hydrochloric Acid (CAS #: 7647-01-0)	**	-	231-595-7	Acute Tox. 3 (H331) Skin Corr. 1A (H314) Press. Gas	Eye Irrit. 2 :: 10%<=C<25% Skin Corr. 1B :: C>=25% Skin Irrit. 2 :: 10%<=C<25% STOT SE 3 :: C>=10%	No data available	No data available
NonHazardous					,		
Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified as hazardous	Not Listed	No data available	No data available
SODIUM CHLORIDÉ	*	-	231-598-3	Not classified	Not Listed	No data	No data

Full text of H- and EUH-phrases: see section 16

<u>Acute Toxicity Estimate</u> No information available

(CAS #: 7647-14-5)

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4	Inhalation LC50 - 4	Inhalation LC50 - 4
			hour - dust/mist -	hour - vapor - mg/L	hour - gas - ppm
			mg/L		
Water	89838.9	No data available	No data available	No data available	No data available
7732-18-5					
SODIUM CHLORIDE	3000	10000	No data available	No data available	No data available
7647-14-5					
Metoclopramide	750	No data available	No data available	No data available	No data available

as hazardous

available

available

Product Name Metoclopramide Injection (Hospira, Inc.) Revision date 19-Dec-2022

Chemical name	Oral LD50	Dermal LD50		Inhalation LC50 - 4 hour - vapor - mg/L	
364-62-5					
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022

Additional information * Proprietary

** to adjust pH

+ Substance with a Union workplace exposure limit

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for

Page 3/13

Version 2

completeness.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation Due to the nature of this material first aid is not normally required.

Eye contact If irritation occurs or persists, get medical attention. Rinse thoroughly with plenty of water,

also under the eyelids.

Skin contactWash exposed area with soap and water, remove contaminated clothing and obtain medical

assistance if irritation occurs.

Ingestion Never give anything by mouth to an unconscious person. Wash out mouth with water. Do

not induce vomiting unless directed by medical personnel. Seek medical attention

immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and

effects

For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media As for primary cause of fire.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the

chemical

Not applicable.

Hazardous combustion products May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen

chloride and other chlorine-containing compounds.

5.3. Advice for firefighters

Product Name Metoclopramide Injection (Hospira, Inc.) Revision date 19-Dec-2022

Special protective equipment for

fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear.

Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be

taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean

spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

See section 8 for more information. See section 13 for more information. Reference to other sections

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Handle in accordance with good industrial hygiene and safety practice. General hygiene considerations

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical product used for nausea and vomiting (antiemetic).

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Metoclopramide

Pfizer OEL TWA-8 Hr: 40 µg/m³

SODIUM CHLORIDE

Latvia 5 mg/m³ Russia MAC: 5 mg/m³

PZ03279

Page 4/13 Version 2

Sodium	

 ACGIH OEL (Ceiling)
 2 mg/m³

 ACGIH TLV
 Ceiling: 2 mg/m³

 Austria
 2 mg/m³

 STEL 4 mg/m³

 Bulgaria
 2.0 mg/m³

 Czech Republic
 1 mg/m³

 Ceiling: 2 mg/m³

 Denmark
 Ceiling: 2 mg/m³

 Estonia
 1 mg/m³

 STEL: 2 mg/m³

 Finland
 Ceiling: 2 mg/m³

 France
 2 mg/m³

 Hungary
 1 mg/m³

 STEL: 2 mg/m³

 Ireland
 STEL: 2 mg/m³

 Ceiling Limit Value
 2 mg/m³

Ceiling Limit Value 2 mg/m³
Latvia 0.5 mg/m³
Poland STEL: 1 mg/m³
0.5 mg/m³
Romania 1 mg/m³
STEL: 3 mg/m³

 Slovakia
 2 mg/m³

 Spain
 STEL: 2 mg/m³

 Switzerland
 2 mg/m³

 STEL: 2 mg/m³

OSHA PEL 2 mg/m³

(vacated) Ceiling: 2 mg/m³
United Kingdom STEL: 2 mg/m³

+ Hydrochloric Acid

ACGIH OEL (Ceiling) 2 ppm
ACGIH TLV Ceiling: 2 ppm

Austria 5 ppm 8 mg/m³ STEL 10 ppm

| STEL 10 ppm | STEL 15 mg/m³ | Bulgaria | STEL: 10 ppm | STEL: 15.0 mg/m³

5 ppm 8.0 mg/m³ Czech Republic 8 mg/m³

Ceiling: 15 mg/m³
Estonia 5 ppm

8 mg/m³
STEL: 10 ppm
STEL: 15 mg/m³
European Union
TWA: 5 ppm
TWA: 8 mg/m³

STEL: 10 ppm STEL: 15 mg/m³ Finland STEL: 5 ppm STEL: 7.6 mg/m³

Germany 2 ppm 3.0 mg/m³

Ceiling / Peak: 4 ppm

Ceiling / Peak: 6 mg/m³
Germany 2 ppm

3 mg/m³ Hungary 8 mg/m³

STEL: 16 mg/m³

Product Name Metoclopramide Injection (Hospira, Inc.)
Revision date 19-Dec-2022 Page 6 / 13
Version 2

Ireland 8 mg/m³

5 ppm

STEL: 10 ppm STEL: 15 mg/m³

Italy 5 ppm

8 mg/m³ STEL: 10 ppm

STEL: 15 mg/m³
Ceiling Limit Value 2 ppm

3.0 mg/m³ 5 ppm 8 mg/m³

STEL: 10 ppm STEL: 15 mg/m³

Netherlands 8 mg/m³

Poland STEL: 15 mg/m³ STEL: 10 mg/m³

5 mg/m³

Romania 5 mg/m²

8 mg/m³ STEL: 10 ppm STEL: 15 mg/m³ MAC: 5 mg/m³ 5 ppm 8.0 mg/m³

 $\begin{array}{cc} \text{Slovakia} & & 5 \text{ ppm} \\ & & 8.0 \text{ mg/m}^3 \\ \text{Spain} & & 5 \text{ ppm} \end{array}$

7.6 mg/m³ STEL: 10 ppm STEL: 15 mg/m³

Switzerland 2 ppm 3 mg/m³

STEL: 4 ppm STEL: 6 mg/m³

U.S. - OSHA - Final PELs - Ceiling Limits 5 ppm 7 mg/m³

OSHA PEL (vacated) Ceiling: 5 ppm

(vacated) Ceiling: 7 mg/m³ Ceiling: 5 ppm

United Kingdom

Ceiling: 7 mg/m³

TWA: 1 ppm

TWA: 2 mg/m³

STEL: 5 ppm STEL: 8 mg/m³

Pfizer Occupational Exposure Band

(OEB) Statement: The purpose of the Occupational Exposure Band (OEB) classification system is to separate

substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to

revision when new information becomes available.

8.2. Exposure controls

Latvia

Russia

Engineering controls Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental exposure controls No information available.

Personal protective equipment Contact your safety and health professional or safety equipment supplier for assistance in

Revision date 19-Dec-2022 Version 2

selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the

selection and use of personal protective equipment (PPE).

Eye/face protection Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is

possible and for bulk processing operations. (Protective gloves must meet the standards in

Page 7 / 13

accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection Impervious protective clothing is recommended if skin contact with drug product is possible

and for bulk processing operations. (Protective clothing must meet the standards in

accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protectionUnder normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10

or international equivalent.)

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Product Name Metoclopramide Injection (Hospira, Inc.)

Physical state Liquid solution
Color Clear, colorless

Odor No information available.
Odor threshold No information available

Molecular formula Mixture
Molecular weight Mixture

<u>Property</u> <u>Values</u>

pHNo data availableMelting point / freezing pointNo data available

Boiling point / boiling range

Flash point

Evaporation rate

No information available

No data available

Flammability (solid, gas)
No data available
Flammability Limit in Air

Upper flammability limit: No data available

Lower flammability limit: No data available

Vapor pressure No data available Vapor density No data available No data available Relative density Water solubility No data available Solubility(ies) No data available **Partition coefficient** No data available **Autoignition temperature** No data available No data available **Decomposition temperature** Kinematic viscosity No data available Dynamic viscosity No data available

Particle characteristics

Particle Size No information available

Revision date 19-Dec-2022 Version 2

Particle Size Distribution Explosive properties

Product Name Metoclopramide Injection (Hospira, Inc.)

No information available No information available

Page 8 / 13

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes

No information available **Oxidizing properties**

None

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No data available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available. Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid None known.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: The information included in this section describes the potential hazards of the individual

ingredients

Short term Accidental ingestion may cause effects similar to those seen in clinical use.

Known Clinical Effects: Therapeutic use of this substance has resulted in weakness, dizziness, drowsiness, ataxia,

confusion, tremors, headache, and gastrointestinal disturbances. As with all antipsychotic agents, tardive dyskinesia may appear. This syndrome is characterized by rhythmical involuntary movements of the tongue, face, mouth, or jaw. Hypersensitivity reactions may

also occur in susceptible individuals.

Acute toxicity Based on available data, the classification criteria are not met.

Serious eye damage/eye irritation
Skin corrosion/irritation
Respiratory or skin sensitization
STOT - single exposure
STOT - repeated exposure
STOT - repeated exposure
Reproductive toxicity

Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.

Germ cell mutagenicity

Carcinogenicity

Aspiration hazard

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Product Name Metoclopramide Injection (Hospira, Inc.) Revision date 19-Dec-2022

Acute Toxicity: (Species, Route, End Point, Dose)

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³

Rat Oral LD 50 3 g/kg Mouse Oral LD 50 4 g/kg Rabbit Dermal LD 50 > 10 g/kg

Metoclopramide

Rat Oral LD 50 750 mg/kg Mouse Oral LD 50 270 mg/kg Rat Intraperitoneal LD 50 114 mg/kg

Sodium hydroxide Mouse IP LD50 40 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
SODIUM CHLORIDE	= 3 g/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 mg/L (Rat)1 h
Metoclopramide	= 750 mg/kg (Rat)	-	-
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-
+ Hydrochloric Acid	238 - 277 mg/kg (Rat)	> 5010 mg/kg (Rabbit)	= 1.68 mg/L (Rat) 1 h

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin irritation Rabbit Mild Eye irritation Rabbit Mild

+ Hydrochloric Acid

Skin irritation Severe

Eye irritation Severe

Sodium hydroxide

Eye Irritation Rabbit Severe Skin Irritation Rabbit Severe

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s)) Metoclopramide

Embryo / Fetal Development Rat Oral 10 mg/kg/day NOEL Not teratogenic

Embryo / Fetal Development Rabbit Oral 10 mg/kg/day NOEL Not Teratogenic

Embryo / Fetal Development Mouse Oral 10 mg/kg/day NOEL Not Teratogenic

Embryo / Fetal Development Rabbit Intravenous 10 mg/kg NOEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

+ Hydrochloric Acid

Bacterial Mutagenicity (Ames) Salmonella Negative

In Vivo Micronucleus Rat Negative

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or

OSHA.

+ Hydrochloric Acid

IARC Group 3 (Not Classifiable)

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

PZ03279

Page 9/13 Version 2

Page 10 / 13

Product Name Metoclopramide Injection (Hospira, Inc.) Revision date 19-Dec-2022

Revision date 19-Dec-2022 Version 2

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should

be avoided.

12.1. Toxicity

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment No information available.

Chemical name	PBT and vPvB assessment
SODIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does
	not apply
Sodium hydroxide	The substance is not PBT / vPvB PBT assessment does
	not apply
+ Hydrochloric Acid	The substance is not PBT / vPvB PBT assessment does
	not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Product Name Metoclopramide Injection (Hospira, Inc.) Revision date 19-Dec-2022

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:
UN proper shipping name:
Not applicable

Special precautions for user: Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water	
CERCLA/SARA Section 313 de minimus % California Proposition 65	Not Listed Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present
SODIUM CHLORIDE	Not Listed
CERCLA/SARA Section 313 de minimus % California Proposition 65	Not Listed Not Listed
TSCA	Present
EINECS	231-598-3
AICS	Present
Metoclopramide	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS Standard for Uniform Scheduling of Medicines and	206-662-9 Schedule 3
Poisons (SUSMP)	Schedule 3
Sodium hydroxide	Ochicadic 4
CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	1000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS AICS	215-185-5 Present
Standard for Uniform Scheduling of Medicines and	Schedule 5
Poisons (SUSMP)	Schedule 6
+ Hydrochloric Acid	30.100.010
CERCLA/SARA Section 313 de minimus %	1.0 %
Hazardous Substances RQs	5000 lb
California Proposition 65	Not Listed
TSCA	Present 231-595-7
EINECS AICS	Present
Standard for Uniform Scheduling of Medicines and	Schedule 5
Poisons (SUSMP)	Schedule 6
•	

Product Name Metoclopramide Injection (Hospira, Inc.) Revision date 19-Dec-2022

Chemical name	French RG number	Title
SODIUM CHLORIDE	RG 78	-
7647-14-5		

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide - 1310-73-2	Use restricted. See item 75.	
+ Hydrochloric Acid - 7647-01-0	Use restricted. See item 75.	

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid - 7647-01-0	25	250

Chemical name	Plant protection products directive (91/414/EEC)
SODIUM CHLORIDE - 7647-14-5	Plant protection agent

Chemical name	EU - Biocides
+ Hydrochloric Acid - 7647-01-0	Product-type 2: Disinfectants and algaecides not intended
·	for direct application to humans or animals

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances **AICS** - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 -Causes severe skin burns and eye damage Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled

Safety data sheets for individual ingredients. Publicly available toxicity information. **Data Sources:**

Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Reason for revision

Ingredients. Updated Section 5 - Fire Fighting Measures. Updated Section 11 - Toxicology

Information. Updated Section 12 - Ecological Information.

PZ03279

Page 12 / 13 Version 2

Page 13 / 13

Product Name Metoclopramide Injection (Hospira, Inc.)
Revision date 19-Dec-2022

Revision date 19-Dec-2022 Version 2

Revision date 19-Dec-2022

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.
